ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1655766
SLC43A2-mediated immune cell infiltration: A Potential therapeutic target in acute myeloid leukemia
Provisionally accepted
- 1Nankai University, Tianjin, China
- 2Tianjin First Central Hospital, Tianjin, China
- 3Tianjin Medical University, Tianjin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Tumor cells compete with T cells for methionine by overexpressing SLC43A2(solute carrier family 43 member 2), leading to T cell exhaustion. However, the correlation between SLC43A2 and immune infiltration or malignant features in acute myeloid leukemia (AML) has rarely been explored. Methods: We obtained gene expression data and clinical information from 173 AML patients in The Cancer Genome Atlas (TCGA) database. Statistical analyses were performed using R (v4.0.5). Differential expression, immune infiltration, functional enrichment, and survival analyses were conducted using online databases, including GEPIA, GSCA Lite, Kaplan–Meier Plotter, KEGG, and TIMER2. In vitro, we established SLC43A2-knockdown cell lines and validated SLC43A2 expression via PCR. Flow cytometry was employed to analyze cell viability, counts, apoptotic cell ratios, and immune cell infiltration. Results: SLC43A2 was highly expressed in AML and associated with poorer survival. Enrichment analysis revealed that SLC43A2 is involved in lymphocyte activation, leukocyte adhesion, and immune response regulatory signaling pathways. Immune infiltration results showed that SLC43A2 positively correlated with immune exhaustion markers (all p < 0.05) and negatively correlated with CD8+ T, NK, and B cell infiltration (all p < 0.05). We constructed an SPI1-hsa-miR-31-5p-SLC43A2 transcriptional network to support the role of SLC43A2. In vitro experiments have shown that SLC43A2 is negatively correlated with the infiltration level of immune cells and positively correlated with the expression levels of PDCD1 and CTLA4. Moreover, lower SLC43A2 expression was associated with enhanced T cell cytotoxicity. Conclusion: The SLC43A2 gene may serve as a diagnostic, prognostic, and potential immune-related biomarker for AML patients. Blocking SLC43A2-associated signaling pathways could provide novel insights into immunotherapy for AML.
Keywords: Acute Myeloid Leukemia, TCGA, SLC43A2, T cells, Immunity
Received: 28 Jun 2025; Accepted: 09 Sep 2025.
Copyright: © 2025 Li, Zhang, Wang, Liu, Zhao, Jiang, Zhang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mingfeng Zhao, Tianjin First Central Hospital, Tianjin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.